Obesity

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2 or greater) with at least […]

Semaglutide 2.4mg (Wegovy), a drug approved for weight loss, can reduce the risk of major adverse cardiovascular events (MACE) by 20%, according to new data released by Novo Nordisk. SELECT is a Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg in adults with established cardiovascular disease (CVD) and overweight or obesity […]

New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, US. The primary […]

Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 billion in 2022, with just under 70% stemming from the US. The predictions come from analysts at Bloomberg Intelligence (BI), who believe securing broad reimbursement and supply are key, with a possible upside from further innovations including combination products. Michael Shah, […]

Eli Lilly’s potential weight-loss drug tirzepatide has shown positive results in a Phase III clinical trial, indicating at the therapy’s potential for patients with obesity and diabetes.   Tirzepatide represents a new class of medicines which are currently being investigated for the treatment of obesity. It works by activating the body’s hormone receptors for glucose-dependent insulinotropic […]